Acquisition Announced Sponsor buyer

Webster Equity Partners acquisition of Lifecore Biomedical

US$664m equity value

Announced 28 Sep 2026 · NASDAQ: LFCR · US$6.28 cash and scrip per share · 50% premium

Advisers

Lifecore Biomedical

Target

Webster Equity Partners

Acquirer

Financial adviser
Legal adviser
Target
Lifecore Biomedical
Acquirer
Webster Equity Partners
Target based in
United States
Buyer based in
United States
Sector
Pharma Services
Tags
Pharma Services, Contract Manufacturing, Life Sciences

In the league tables

Similar deals

All pharma services deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.